COVID -

MMWR Booster for: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022, Weekly / December 2, 2022 / 71(48);1526–1530

Posted on January 10, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways Bivalent Boosters’ Effectiveness: The study reveals that bivalent mRNA COVID-19 boosters offer significant additional protection against symptomatic SARS-CoV-2 infection, especially for those who had 2 to 4

MMWR Booster for: Prevalence of SARS-CoV-2 and Influenza Coinfection and Clinical Characteristics Among Children and Adolescents Aged <18 Years Who Were Hospitalized or Died with Influenza — United States, 2021–22 Influenza Season, Weekly / December 16, 2022 / 71(50);1589–1596

Posted on January 5, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways 6% of pediatric influenza hospitalizations had concurrent SARS-CoV-2 (COVID) coinfection during the 2021–22 influenza season. Coinfected patients exhibited a higher need for respiratory support (invasive or noninvasive)

MMWR Booster for: COVID-19 and Other Underlying Causes of Cancer Deaths — United States, January 2018–July 2022, Weekly / December 16, 2022 / 71(50);1583–1588

Posted on January 5, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways: Increased Risk for Cancer Patients: Individuals with cancer showed an elevated risk of dying from COVID-19, with 2.0% in 2020 and 2.4% in 2021 having COVID-19 as

MMWR Booster for: Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022, Weekly / December 30, 2022 / 71(5152);1616–1624

Posted on January 3, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways: Bivalent mRNA Vaccine Effectiveness: The study found that bivalent mRNA vaccines are effective in preventing COVID-19–associated emergency department/urgent care encounters and hospitalizations among immunocompetent adults. Comparative Analysis:

MMWR Booster for: Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022, Weekly / December 30, 2022 / 71(5152);1625–1630

Posted on January 2, 2024 by Cody Micah Carmichael MPH, CPH

Top 5 Takeaways 1. Effectiveness of Bivalent Booster: The study found an 84% effectiveness of the bivalent booster against COVID-19 hospitalization compared to unvaccinated individuals. 2. Relative Vaccine Effectiveness: Compared

Posted on January 1, 2024 by Cody Micah Carmichael MPH, CPH

In this entry of MMWR Booster, a summary is provided about findings regarding COVID mRNA Vaccine effectiveness in preventing severe hopsitalizations and outcomes.

Epidemiology, Broadly Speaking

Tag: COVID